Pfizer Global R&D president Dr. John LaMattina will retire from Pfizer by the end of this year, after 30 years with the company. Pfizer has begun a search both inside and outside the company for his successor, and Dr. LaMattina will remain during this period to ensure a smooth transition, according to the company. Chief financial officer Alan Levin has resigned to “pursue career opportunities outside Pfizer” after 20 years with the company. Speaking on Dr. LaMattina’s re...